The association between irAE occurrence and improved benefit to anti-PD-1 ICI in terms of response and PFS has previously been reported in ICI-treated melanoma patients (14, 17); although a recent pooled analysis of KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006 studies that corrected for immortal time bias suggested similar ORR, PFS and OS statistics among patients who did or did not experience irAEs (39). The gene discussed is PDCD1; the disease is melanoma.